Regarding the BOD citing risks. These risks are in relation to company staying public, especially if we head into a recession. Whereas this is a non-issue if they're under Pfizer, as Pfizer have plenty of cash, so giving them several million (or more) each year for R&D is not a problem for them. Also part of the risks are in relation to commercialisation, but I don't think Pfizer have any interest in the business of RAP, my thoughts are that their main interest is just in the COVID diagnosis as they can leverage that to sell more of their COVID antiviral drug. Since they probably realise that testing will continually drop off around the world as many governments aren't pushing it so hard anymore/have become more relax, some people will keep using RATs but as they're an expenditure I wouldn't be surprised if demand for those drops off overtime too. However if there was a free COVID test that people could take, right on their smartphone (so minimal effort involved), then they might be able to retain this high level of testing. So then whenever someone tests positive they can push a recommendation for them to go seek out the drug/a prescription for the drug. And Pfizer knowing they have RAP under them gives them a lot more reassurance (they know RAP will have access to the money needed to develop the tool, they can make RAP focus their efforts on what matters to Pfizer, and there's no risk of a competitor coming in and making some better deal to gain exclusive access to it).
Assuming the above is correct then Pfizer will be valuing it based on how much they expect to make off the drug at current and future market testing conditions, compared to how much they'd expect to make if there was a free and convenient COVID test. So as long as it's a reasonable percentage of that they'd probably still be interested, but I don't think we'll see an offer at the levels many people here are hoping for (although the question would be what price is needed to capture enough of the yes vote). Either way if they walk, I think they'll still work with RAP.
RAP Price at posting:
13.5¢ Sentiment: Buy Disclosure: Held
